AK135
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Conditions
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Trial Timeline
Feb 28, 2025 → Dec 31, 2027
NCT ID
NCT06860789About AK135
AK135 is a phase 1 stage product being developed by Akeso for Chemotherapy-induced Peripheral Neuropathy (CIPN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06860789. Target conditions include Chemotherapy-induced Peripheral Neuropathy (CIPN).
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-induced Peripheral Neuropathy (CIPN) were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06860789 | Phase 1 | Recruiting |
Competing Products
20 competing products in Chemotherapy-induced Peripheral Neuropathy (CIPN)